Immatics' IMA402 shows 32% confirmed response rate in high-PRAME melanoma patients in Phase 1b trial

Bitget2026/10/26 11:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immatics announced updated early-stage trial results showing tumor responses across advanced solid cancers for IMA402 bispecific therapy and IMA203CD8 cell therapy.
IMA402 showed durable responses in advanced melanoma with favorable tolerability; results will be presented at the 2026 ESMO meeting.
IMA203CD8 results already presented at ESMO showed durable responses across several cancers, including gynecologic tumors, with manageable safety.
Development plans include IMA402 combination treatments, with initial lung cancer combination data expected in 2027.
A pediatric cancer trial of IMA203CD8 is planned for the first half of 2027, supporting potential use across tumor types.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950103-26-016136), on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03

Nvidia continues to plummet, losing $430 billion in market value over two days, with Microsoft temporarily reclaiming the world's second place.

On Tuesday, Nvidia closed down 5.5%, a decline significantly greater than other major tech stocks, making it a key factor dragging down the tech sector's performance. During intraday trading on Tuesday, Microsoft's market capitalization briefly surpassed Nvidia, making it the world's second largest publicly traded company by market value. However, after Anthropic released its office suite, Microsoft's losses widened, causing it to fall behind Nvidia once again.

华尔街见闻•2026/11/10 23:01